nach oben

Erschienen in:

01.09.2014 | Review Article

Key facts and hot spots on tumor necrosis factor receptor‐associated periodic syndrome

verfasst von: Donato Rigante, Giuseppe Lopalco, Antonio Vitale, Orso Maria Lucherini, Caterina De Clemente, Francesco Caso, Giacomo Emmi, Luisa Costa, Elena Silvestri, Laura Andreozzi, Florenzo Iannone, Mauro Galeazzi, Luca Cantarini

Erschienen in: Clinical Rheumatology | Ausgabe 9/2014

Einloggen, um Zugang zu erhalten

Abstract

Tumor necrosis factor receptor-associated periodic syndrome (TRAPS), formerly known as familial Hibernian fever, is the most common autosomal dominant autoinflammatory disease, resulting from mutations in the TNFRSF1A gene, encoding the 55-kD tumor necrosis factor receptor. The pathophysiologic mechanism of TRAPS remains ambiguous and only partially explained. The onset age of the syndrome is variable and the clinical scenery is characterized by recurrent episodes of high-grade fever that typically lasts 1–3 weeks, associated with migrating myalgia, pseudocellulitis, diffuse abdominal pain, appendicitis-like findings, ocular inflammatory signs, and risk of long-term amyloidosis. Fever episodes are responsive to high-dose corticosteroids, but different classes of drugs have been reported to be ineffective. The use of etanercept is unable to control systemic inflammation, while interleukin-1 blockade has been shown as effective in the control of disease activity in many patients reported so far.

Touitou I, Koné-Paut I (2008) Autoinflammatory diseases. Best Pract Res Clin Rheumatol 22:811–829PubMedCrossRef

McGonagle D, McDermott MF (2006) A proposed classification of the immunological diseases. PLoS Med 3:e297PubMedCentralPubMedCrossRef

Drenth JP, van der Meer JW (2006) The inflammasome—a linebacker of innate defense. N Engl J Med 355:730–732PubMedCrossRef

Rigante D (2012) The fresco of autoinflammatory diseases from the pediatric perspective. Autoimmun Rev 11:348–356PubMedCrossRef

Gattorno M, Federici S, Pelagatti MA, Caorsi R, Brisca G, Malattia C et al (2008) Diagnosis and management of autoinflammatory diseases in childhood. J Clin Immunol 28(Suppl 1):S73–S83PubMedCrossRef

Rigante D (2009) Autoinflammatory syndromes behind the scenes of recurrent fevers in children. Med Sci Monit 15:RA179–RA187PubMed

Williamson LM, Hull D, Mehta R, Reeves WG, Robinson BH, Toghill PJ (1982) Familial Hibernian fever. Q J Med 51:469–480PubMed

McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M et al (1999) Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 97:133–144PubMedCrossRef

Aganna E, Hammond L, Hawkins PN, Aldea A, McKee SA, van Amstel HK et al (2003) Heterogeneity among patients with tumor necrosis factor receptor-associated periodic syndrome phenotypes. Arthritis Rheum 48:2632–2644PubMedCrossRef

10.

Aksentijevich I, Galon J, Soares M, Mansfield E, Hull K, Oh HH et al (2001) The tumor-necrosis-factor receptor-associated periodic syndrome: new mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers. Am J Hum Genet 69:301–314PubMedCentralPubMedCrossRef

11.

Cantarini L, Lucherini OM, Cimaz R, Brizi MG, Galeazzi M (2010) Serosal involvement in adult-onset autoinflammatory disorders. Respiration 80:260–261PubMedCrossRef

12.

Cantarini L, Lucherini OM, Brucato A, Barone L, Cumetti D, Iacoponi F et al (2012) Clues to detect tumor necrosis factor receptor-associated periodic syndrome (TRAPS) among patients with idiopathic recurrent acute pericarditis: results of a multicentre study. Clin Res Cardiol 101:525–531PubMedCrossRef

13.

Cantarini L, Lucherini OM, Baldari CT, Laghi Pasini F, Galeazzi M (2010) Familial clustering of recurrent pericarditis may disclose tumour necrosis factor receptor-associated periodic syndrome. Clin Exp Rheumatol 28:405–407PubMed

14.

Cantarini L, Lucherini OM, Cimaz R, Baldari CT, Bellisai F, Rossi Paccani S et al (2009) Idiopathic recurrent pericarditis refractory to colchicine treatment can reveal tumor necrosis factor receptor-associated periodic syndrome. Int J Immunopathol Pharmacol 22:1051–1058PubMed

15.

Cantarini L, Lucherini OM, Cimaz R, Baldari CT, Laghi Pasini F, Galeazzi M (2010) Sacroileitis and pericarditis: atypical presentation of tumor necrosis factor receptor-associated periodic syndrome and response to etanercept therapy. Clin Exp Rheumatol 28:290–291PubMed

16.

Lainka E, Neudorf U, Lohse P, Timmann C, Stojanov S, Huss K et al (2009) Incidence of TNFRSF1A mutations in German children: epidemiological, clinical and genetic characteristics. Rheumatology (Oxford) 48:987–991CrossRef

17.

Hull KM, Drewe E, Aksentijevich I, Singh HK, Wong K, McDermott EM et al (2002) The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore) 81:349–368CrossRef

18.

Kusuhara K, Nomura A, Nakao F, Hara T (2004) Tumour necrosis factor receptor-associated periodic syndrome with a novel mutation in the TNFRSF1A gene in a Japanese family. Eur J Pediatr 163:30–32PubMedCrossRef

19.

McDermott MF, Ogunkolade BW, McDermott EM, Jones LC, Wan Y, Quane KA et al (1998) Linkage of familial Hibernian fever to chromosome 12p13. Am J Hum Genet 62:1446–1451PubMedCentralPubMedCrossRef

20.

Mulley J, Saar K, Hewitt G, Ruschendorf F, Phillips H, Colley A et al (1998) Gene localization for an autosomal dominant familial periodic fever to 12p13. Am J Hum Genet 62:884–889PubMedCentralPubMedCrossRef

21.

Turner MD, Chaudhry A, Nedjai B (2012) Tumour necrosis factor receptor trafficking dysfunction opens the TRAPS door to pro-inflammatory cytokine secretion. Biosci Rep 32:105–112PubMedCentralPubMedCrossRef

22.

Rebelo SL, Bainbridge SE, Amel-Kashipaz MR, Radford PM, Powell RJ, Todd I et al (2006) Modeling of tumor necrosis factor receptor superfamily 1A mutants associated with tumor necrosis factor receptor-associated periodic syndrome indicates misfolding consistent with abnormal function. Arthritis Rheum 54:2674–2687PubMedCrossRef

23.

Cantarini L, Rigante D, Merlini G, Vitale A, Caso F, Lucherini OM et al (2013) The expanding spectrum of low-penetrance TNFRSF1A gene variants in adults presenting with recurrent inflammatory attacks: clinical manifestations and long-term follow-up. Semin Arthritis Rheum. doi:10.1016/j.semarthrit.2013.12.002 PubMed

24.

Sarrauste de Menthiere C, Terriere S, Pugnere D, Ruiz M, Demaille J, Touitou I (2003) INFEVERS: the Registry for FMF and hereditary inflammatory disorders mutations. Nucleic Acids Res 31:282–285PubMedCentralPubMedCrossRef

25.

Lobito AA, Gabriel TL, Medema JP, Kimberley FC (2011) Disease causing mutations in the TNF and TNFR superfamilies: focus on molecular mechanisms driving disease. Trends Mol Med 17:494–505PubMedCrossRef

26.

Bazzoni F, Beutler B (1996) The tumor necrosis factor ligand and receptor families. N Engl J Med 334:1717–1725PubMedCrossRef

27.

Gommerman JL, Browning JL (2003) Lymphotoxin/light, lymphoid microenvironments and autoimmune disease. Nat Rev Immunol 3:642–655PubMed

28.

Schottelius AJ, Moldawer LL, Dinarello CA, Asadullah K, Sterry W, Edwards CK 3rd (2004) Biology of tumor necrosis factor-alpha—implications for psoriasis. Exp Dermatol 13:193–222PubMedCrossRef

29.

Kollias G (2005) TNF pathophysiology in murine models of chronic inflammation and autoimmunity. Semin Arthritis Rheum 34:3–6PubMedCrossRef

30.

Aloisi F, Pujol-Borrell R (2006) Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 6:205–217PubMed

31.

Brennan FM, Maini RN, Feldmann M (1995) Cytokine expression in chronic inflammatory disease. Br Med Bull 51:368–384PubMed

32.

Beutler B, Cerami A (1989) The biology of cachectin/TNF—a primary mediator of the host response. Annu Rev Immunol 7:625–655PubMedCrossRef

33.

Ware CF, Crowe PD, Grayson MH, Androlewicz MJ, Browning JL (1992) Expression of surface lymphotoxin and tumor necrosis factor on activated T, B, and natural killer cells. J Immunol 149:3881–3888PubMed

34.

Vassalli P (1992) The pathophysiology of tumor necrosis factors. Annu Rev Immunol 10:411–452PubMedCrossRef

35.

Wajant H, Pfizenmaier K, Scheurich P (2003) Tumor necrosis factor signaling. Cell Death Differ 10:45–65PubMedCrossRef

36.

Kimberley FC, Lobito AA, Siegel RM, Screaton GR (2007) Falling into TRAPS—receptor misfolding in the TNF receptor 1-associated periodic fever syndrome. Arthritis Res Ther 9:217PubMedCentralPubMedCrossRef

37.

Banner DW, D'Arcy A, Janes W, Gentz R, Schoenfeld HJ, Broger C et al (1993) Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 73:431–445PubMedCrossRef

38.

Magnotti F, Vitale A, Rigante D, Lucherini OM, Cimaz R, Muscari I et al (2013) The most recent advances in pathophysiology and management of tumour necrosis factor receptor-associated periodic syndrome (TRAPS): personal experience and literature review. Clin Exp Rheumatol 31:141–149PubMed

39.

Lobito AA, Kimberley FC, Muppidi JR, Komarow H, Jackson AJ, Hull KM et al (2006) Abnormal disulfide-linked oligomerization results in ER retention and altered signaling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). Blood 108:1320–1327PubMedCentralPubMedCrossRef

40.

Huggins ML, Radford PM, McIntosh RS, Bainbridge SE, Dickinson P, Draper-Morgan KA et al (2004) Shedding of mutant tumor necrosis factor receptor superfamily 1A associated with tumor necrosis factor receptor-associated periodic syndrome: differences between cell types. Arthritis Rheum 50:2651–2659PubMedCrossRef

41.

Kallinich T, Briese S, Roesler J, Rudolph B, Sarioglu N, Blankenstein O et al (2004) Two familial cases with tumor necrosis factor receptor-associated periodic syndrome caused by a non-cysteine mutation (T50M) in the TNFRSF1A gene associated with severe multiorganic amyloidosis. J Rheumatol 31:2519–2522PubMed

42.

Stojanov S, Dejaco C, Lohse P, Huss K, Duftner C, Belohradsky BH et al (2008) Clinical and functional characterisation of a novel TNFRSF1A c.605 T > A/V173D cleavage site mutation associated with tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS), cardiovascular complications and excellent response to etanercept treatment. Ann Rheum Dis 67:1292–1298PubMedCrossRef

43.

Park H, Bourla AB, Kastner DL, Colbert RA, Siegel RM (2012) Lighting the fires within: the cell biology of autoinflammatory diseases. Nat Rev Immunol 12:570–580PubMed

44.

Simon A, Park H, Maddipati R, Lobito AA, Bulua AC, Jackson AJ et al (2010) Concerted action of wild-type and mutant TNF receptors enhances inflammation in TNF receptor 1-associated periodic fever syndrome. Proc Natl Acad Sci U S A 107:9801–9806PubMedCentralPubMedCrossRef

45.

Bulua AC, Simon A, Maddipati R, Pelletier M, Park H, Kim KY et al (2011) Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). J Exp Med 208:519–533PubMedCentralPubMedCrossRef

46.

Kamata H, Honda S, Maeda S, Chang L, Hirata H, Karin M (2005) Reactive oxygen species promote TNF alpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 120:649–661PubMedCrossRef

47.

Dickie LJ, Aziz AM, Savic S, Lucherini OM, Cantarini L, Geiler J et al (2012) Involvement of X-box binding protein 1 and reactive oxygen species pathways in the pathogenesis of tumour necrosis factor receptor-associated periodic syndrome. Ann Rheum Dis 71:2035–2043PubMedCrossRef

48.

Pahl HL, Baeuerle PA (1997) The ER-overload response: activation of NF-kappa B. Trends Biochem Sci 22:63–67PubMedCrossRef

49.

Bernales S, Papa FR, Walter P (2006) Intracellular signaling by the unfolded protein response. Annu Rev Cell Dev Biol 22:487–508PubMedCrossRef

50.

Bachetti T, Chiesa S, Castagnola P, Bani D, Di Zanni E, Omenetti A et al (2013) Autophagy contributes to inflammation in patients with TNFR-associated periodic syndrome (TRAPS). Ann Rheum Dis 72:1044–1052PubMedCrossRef

51.

Ceribelli A, Yao B, Dominguez-Gutierrez PR, Nahid MA, Satoh M, Chan EK (2011) MicroRNAs in systemic rheumatic diseases. Arthritis Res Ther 13:229PubMedCentralPubMedCrossRef

52.

Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, He J et al (2010) Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 31:659–666PubMedCrossRef

53.

Lucherini OM, Obici L, Ferracin M, Fulci V, McDermott MF, Merlini G et al (2013) First report of circulating microRNAs in tumour necrosis factor receptor-associated periodic syndrome (TRAPS). PLoS One 8:e73443CrossRef

54.

Rittore C, Sanchez E, Soler S, Barat-Houari M, Albers M, Obici L et al (2014) Identification of a new exon 2-skipped TNFR1 transcript: regulation by three functional polymorphisms of the TNFR-associated periodic syndrome (TRAPS) gene. Ann Rheum Dis 73:290–297PubMedCrossRef

55.

Cantarini L, Lucherini OM, Iacoponi F, Cimaz R, Simonini G, Rigante D et al (2010) Development and preliminary validation of a diagnostic score for identifying patients affected with adult-onset autoinflammatory disorders. Int J Immunopathol Pharmacol 23:1133–1141PubMed

56.

Cantarini L, Vitale A, Lucherini OM, Muscari I, Magnotti F, Brizi G et al (2013) Childhood versus adulthood-onset autoinflammatory disorders: myths and truths intertwined. Reumatismo 65:55–62PubMedCrossRef

57.

Stojanov S, McDermott MF (2005) The tumour necrosis factor receptor-associated periodic syndrome: current concepts. Expert Rev Mol Med 7:1–18PubMedCrossRef

58.

Dodé C, Andre M, Bienvenu T, Hausfater P, Pecheux C, Bienvenu J et al (2002) The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 46:2181–2188PubMedCrossRef

59.

Rigante D, Frediani B, Galeazzi M, Cantarini L (2013) From the Mediterranean to the sea of Japan: the transcontinental odyssey of autoinflammatory diseases. Biomed Res Int 2013:485103PubMedCentralPubMedCrossRef

60.

Cantarini L, Lucherini OM, Cimaz R, Rigante D, Baldari CT, Laghi Pasini F et al (2012) Typical and severe tumor necrosis factor receptor-associated periodic syndrome in the absence of mutations in the TNFRSF1A gene: a case series. Rheumatol Int 32:4015–4018PubMedCrossRef

61.

Lachmann HJ, Papa R, Gerhold K, Obici L, Touitou I, Cantarini L et al (2013) The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Ann Rheum Dis. doi:10.1136/annrheumdis-2013-204184

62.

Cantarini L, Lucherini OM, Cimaz R, Galeazzi M (2010) Recurrent pericarditis caused by a rare mutation in the TNFRSF1A gene and with excellent response to anakinra treatment. Clin Exp Rheumatol 28:802PubMed

63.

Toro JR, Aksentijevich I, Hull K, Dean J, Kastner DL (2000) Tumor necrosis factor receptor-associated periodic syndrome: a novel syndrome with cutaneous manifestations. Arch Dermatol 136:1487–1494PubMed

64.

Rigante D, Cantarini L (2011) Monogenic autoinflammatory syndromes at a dermatological level. Arch Dermatol Res 303:375–380PubMedCrossRef

65.

Schmaltz R, Vogt T, Reichrath J (2010) Skin manifestations in tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Dermatoendocrinol 2:26–29PubMedCentralPubMedCrossRef

66.

Hull KM, Wong K, Wood GM, Chu WS, Kastner DL (2002) Monocytic fasciitis: a newly recognized clinical feature of tumor necrosis factor receptor dysfunction. Arthritis Rheum 46:2189–2194PubMedCrossRef

67.

Caso F, Rigante D, Vitale A, Lucherini OM, Costa L, Atteno M et al (2013) Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues. Int J Rheumatol. doi:10.1155/2013/513782 PubMedCentralPubMed

68.

Haas SL, Lohse P, Schmitt WH, Hildenbrand R, Karaorman M, Singer MV et al (2006) Severe TNF receptor-associated periodic syndrome due to 2 TNFRSF1A mutations including a new F60V substitution. Gastroenterology 130:172–178PubMedCrossRef

69.

Yao Q, Englund KA, Hayden SP, Tomecki KJ (2012) Tumor necrosis factor receptor associated periodic fever syndrome with photographic evidence of various skin disease and unusual phenotypes: case report and literature review. Semin Arthritis Rheum 41:611–617PubMedCrossRef

70.

Minden K, Aganna E, McDermott MF, Zink A (2004) Tumour necrosis factor receptor associated periodic syndrome (TRAPS) with central nervous system involvement. Ann Rheum Dis 63:1356–1357PubMedCentralPubMedCrossRef

71.

Wildemann B, Rudofsky G Jr, Kress B, Jarius S, Konig F, Schwenger V (2007) The tumor-necrosis-factor-associated periodic syndrome, the brain, and tumor-necrosis-factor-alpha antagonists. Neurology 68:1742–1744PubMedCrossRef

72.

Obici L, Merlini G (2012) Amyloidosis in autoinflammatory syndromes. Autoimmun Rev 12:14–17PubMedCrossRef

73.

Rigante D, Capoluongo E (2011) The plodding diagnosis of monogenic autoinflammatory diseases in childhood: from the clinical scenery to laboratory investigation. Clin Chem Lab Med 49:783–791PubMed

74.

Pelagatti MA, Meini A, Caorsi R, Cattalini M, Federici S, Zulian F et al (2011) Long-term clinical profile of children with the low-penetrance R92Q mutation of the TNFRSF1A gene. Arthritis Rheum 63:1141–1150PubMedCentralPubMedCrossRef

75.

Ravet N, Rouaghe S, Dode C, Bienvenu J, Stirnemann J, Levy P et al (2006) Clinical significance of P46L and R92Q substitutions in the tumour necrosis factor superfamily 1A gene. Ann Rheum Dis 65:1158–1162PubMedCentralPubMedCrossRef

76.

Cantarini L, Lucherini OM, Cimaz R, Brizi MG, Galeazzi M (2011) Autoinflammatory disorders and patients with isolated serosal involvement. Rheumatol Int 31:979–980PubMedCrossRef

77.

Cantarini L, Imazio M, Brizi MG, Lucherini OM, Brucato A, Cimaz R et al (2013) Role of autoimmunity and autoinflammation in the pathogenesis of idiopathic recurrent pericarditis. Clin Rev Allergy Immunol 44:6–13PubMedCrossRef

78.

Cantarini L, Lucherini OM, Vitale A, Sabadini L, Brizi MG, Frediani B et al (2013) Expanding spectrum of TNFRSF1A gene mutations among patients with idiopathic recurrent acute pericarditis. Intern Med J 43:725–727PubMedCrossRef

79.

Cantarini L, Imazio M, Brucato A, Lucherini OM, Galeazzi M (2010) Innate versus acquired immune response in the pathogenesis of recurrent idiopathic pericarditis. Autoimmun Rev 9:436–440PubMedCrossRef

80.

Rigante D, Cantarini L, Imazio M, Lucherini OM, Sacco E, Galeazzi M et al (2011) Autoinflammatory diseases and cardiovascular manifestations. Ann Med 43:341–346PubMedCrossRef

81.

Trost S, Rose CD (2005) Myocarditis and sacroiliitis: 2 previously unrecognized manifestations of tumor necrosis factor receptor associated periodic syndrome. J Rheumatol 32:175–177PubMed

82.

Roubille F, Cayla G, Gahide G, Mourad G, Macia JC (2009) Acute myocarditis and tumor necrosis factor receptor-associated periodic (TRAP) syndrome: first case described and discussion. Eur J Intern Med 20:e25–e26PubMedCrossRef

83.

Chia S, Qadan M, Newton R, Ludlam CA, Fox KA, Newby DE (2003) Intra-arterial tumor necrosis factor-alpha impairs endotheliumdependent vasodilatation and stimulates local tissue plasminogen activator release in humans. Arterioscler Thromb Vasc Biol 23:695–701PubMedCrossRef

84.

Muscari I, Iacoponi F, Cantarini L, Lucherini OM, Simonini G, Brizi MG et al (2012) The diagnostic evaluation of patients with potential adult-onset autoinflammatory disorders: our experience and review of the literature. Autoimmun Rev 12:10–13PubMedCrossRef

85.

Cantarini L, Iacoponi F, Lucherini OM, Obici L, Brizi MG, Cimaz R et al (2011) Validation of a diagnostic score for the diagnosis of autoinflammatory diseases in adults. Int J Immunopathol Pharmacol 24:695–702PubMed

86.

Manukyan G, Ghazaryan K, Ktsoyan Z, Khachatryan Z, Kelly D, Tatyan M et al (2010) Comparative analysis of cytokine profiles in autoinflammatory and autoimmune conditions. Cytokine 50:146–151PubMedCrossRef

87.

Husby G, Husebekk A, Skogen B, Sletten K, Marhaug G, Magnus J et al (1988) Serum amyloid A (SAA)-the precursor of protein AA in secondary amyloidosis. Adv Exp Med Biol 243:185–192PubMedCrossRef

88.

Yang Z, Tao T, Raftery MJ, Youssef P, Di Girolamo N, Geczy CL (2001) Proinflammatory properties of the human S100 protein S100A12. J Leukoc Biol 69:986–994PubMed

89.

Cantarini L, Rigante D, Brizi MG, Lucherini OM, Sebastiani GD, Vitale A et al (2012) Clinical and biochemical landmarks in systemic autoinflammatory diseases. Ann Med 44:664–673PubMedCrossRef

90.

Cantarini L, Obici L, Simonini G, Cimaz R, Bacarelli MR, Merlini G et al (2012) Serum leptin, resistin, visfatin and adiponectin levels in tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Clin Exp Rheumatol 30:S108–S114PubMed

91.

Cantarini L, Lucherini OM, Muscari I, Frediani B, Galeazzi M, Brizi MG et al (2012) Tumour necrosis factor receptor-associated periodic syndrome (TRAPS): state of the art and future perspectives. Autoimmun Rev 12:38–43PubMedCrossRef

92.

Ter Haar N, Lachmann H, Ozen S, Woo P, Uziel Y, Modesto C et al (2013) Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis 72:678–685PubMedCrossRef

93.

Cantarini L, Lucherini OM, Galeazzi M, Fanti F, Simonini G, Baldari CT et al (2009) Tumour necrosis factor receptor-associated periodic syndrome caused by a rare mutation in the TNFRSF1A gene, and with excellent response to etanercept treatment. Clin Exp Rheumatol 27:890–891PubMed

94.

Cantarini L, Rigante D, Lucherini OM, Cimaz R, Laghi Pasini F, Baldari CT et al (2010) Role of etanercept in the treatment of tumor necrosis factor receptor-associated periodic syndrome: personal experience and review of the literature. Int J Immunopathol Pharmacol 23:701–707PubMed

95.

Bulua AC, Mogul DB, Aksentijevich I, Singh H, He DY, Muenz LR et al (2012) Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study. Arthritis Rheum 64:908–913PubMedCrossRef

96.

Drewe E, Huggins ML, Morgan AG, Cassidy MJ, Powell RJ (2004) Treatment of renal amyloidosis with etanercept in tumour necrosis factor receptor-associated periodic syndrome. Rheumatology (Oxford) 43:1405–1408CrossRef

97.

Simsek I, Kaya A, Erdem H, Pay S, Yenicesu M, Dinc A (2010) No regression of renal amyloid mass despite remission of nephrotic syndrome in a patient with TRAPS following etanercept therapy. J Nephrol 23:119–123PubMed

98.

Gattorno M, Pelagatti MA, Meini A, Obici L, Barcellona R, Federici S et al (2008) Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 58:1516–1520PubMedCrossRef

99.

Jacobelli S, Andre M, Alexandra JF, Dode C, Papo T (2007) Failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS). Rheumatology (Oxford) 46:1211–1212CrossRef

100.

Nedjai B, Hitman GA, Quillinan N, Coughlan RJ, Church L, McDermott MF et al (2009) Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 60:619–625PubMedCrossRef

101.

Drewe E, Powell RJ, McDermott EM (2007) Comment on: Failure of anti-TNF therapy in TNF receptor 1-associated periodic syndrome (TRAPS). Rheumatology (Oxford) 46:1865–1866CrossRef

102.

Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D et al (2002) Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 301:418–426PubMedCrossRef

103.

Vitale A, Rigante D, Lucherini OM, Caso F, Muscari I, Magnotti F et al (2013) Biological treatments: new weapons in the management of monogenic autoinflammatory disorders. Mediat Inflamm 2013:939847CrossRef

104.

Sacre K, Brihaye B, Lidove O, Papo T, Pocidalo MA, Cuisset L et al (2008) Dramatic improvement following interleukin 1beta blockade in tumor necrosis factor receptor-1-associated syndrome (TRAPS) resistant to anti-TNF-alpha therapy. J Rheumatol 35:357–358PubMed

105.

Obici L, Meini A, Cattalini M, Chicca S, Galliani M, Donadei S et al (2011) Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis. Ann Rheum Dis 70:1511–1512PubMedCrossRef

106.

Quillinan N, Mannion G, Mohammad A, Coughlan R, Dickie LJ, McDermott MF et al (2011) Failure of sustained response to etanercept and refractoriness to anakinra in patients with T50M TNF-receptor-associated periodic syndrome. Ann Rheum Dis 70:1692–1693PubMedCrossRef

107.

Brizi MG, Galeazzi M, Lucherini OM, Cantarini L, Cimaz R (2012) Successful treatment of tumor necrosis factor receptor-associated periodic syndrome with canakinumab. Ann Intern Med 156:907–908PubMedCrossRef

108.

Arad U, Niv E, Caspi D, Elkayam O (2012) “TRAP” the diagnosis: a man with recurrent episodes of febrile peritonitis, not just familial Mediterranean fever. Isr Med Assoc J 14:229–231PubMed

109.

Gattorno M, Obici L, Meini A, Tormey V, Abrams K, Davis N et al (2012) Efficacy and safety of canakinumab in patients with TNF receptor associated periodic syndrome [abstract]. Arthritis Rheum 64:749

110.

Lopalco G, Rigante D, Vitale A, Frediani B, Iannone F, Cantarini L (2014) Tumor necrosis factor receptor-associated periodic syndrome managed with the couple canakinumab-alendronate. Clin Rheumatol Mar 11 - Epub ahead of print

111.

Cantarini L, Vitale A, Magnotti F, Lucherini OM, Caso F, Frediani B et al (2013) Weekly oral alendronate in mevalonate kinase deficiency. Orphanet J Rare Dis 8:196PubMedCentralPubMedCrossRef

112.

Nowlan ML, Drewe E, Bulsara H, Esposito N, Robins RA, Tighe PJ et al (2006) Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A. Rheumatology (Oxford) 45:31–37CrossRef

113.

Vaitla PM, Radford PM, Tighe PJ, Powell RJ, McDermott EM, Todd I et al (2011) Role of interleukin-6 in a patient with tumor necrosis factor receptor-associated periodic syndrome: assessment of outcomes following treatment with the anti-interleukin-6 receptor monoclonal antibody tocilizumab. Arthritis Rheum 63:1151–1155PubMedCrossRef

Titel: Key facts and hot spots on tumor necrosis factor receptor‐associated periodic syndrome
verfasst von: Donato Rigante
Giuseppe Lopalco
Antonio Vitale
Orso Maria Lucherini
Caterina De Clemente
Francesco Caso
Giacomo Emmi
Luisa Costa
Elena Silvestri
Laura Andreozzi
Florenzo Iannone
Mauro Galeazzi
Luca Cantarini
Publikationsdatum: 01.09.2014
Verlag: Springer London
Erschienen in: Clinical Rheumatology / Ausgabe 9/2014
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-014-2722-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2014

Does vitamin D affect femoral cartilage thickness? An ultrasonographic study

Health care in systemic lupus erythematosus (SLE): the patient’s perspective

Cytochrome P450 interactions and clinical implication in rheumatology

Evaluation of a new erosion score by musculoskeletal ultrasound in patients with rheumatoid arthritis

New gout test: enhanced ex vivo cytokine production from PBMCS in common gout patients and a gout patient with Kearns-Sayre syndrome